A New Neurobiological Lever for Your Most Stuck Patients
If you have been practicing long enough, you know the feeling: a patient who is insightful, committed, showing up every week, yet somehow stuck. The narrative shifts, the homework gets done, and still the same emotional wall stays in place. What if that wall were partly biological?
Spravato (esketamine) is an FDA-approved nasal spray that works through a mechanism entirely different from any antidepressant you have seen prescribed. It does not just manage symptoms. It temporarily rewires the brain itself, creating a window of enhanced neuroplasticity during which therapeutic work can land more deeply than it ever could before.
This newsletter is our attempt to share the science with you plainly and to explore how our clinic and your practice might work together to help the patients who need it most.
What Spravato Is (and Is Not)
Spravato is the S-enantiomer of ketamine, meaning it is the more pharmacologically active half of the same molecule. Unlike street ketamine or IV infusions administered in non-clinical settings, Spravato is FDA-approved, delivered as a calibrated nasal spray, and administered in a certified clinical setting with a mandatory monitoring period. It is a Schedule III controlled substance.
It is currently FDA-approved for:
- Treatment-Resistant Depression (TRD) in adults who have failed at least two adequate antidepressant trials
- Major Depressive Disorder with acute suicidal ideation or behavior (MDSI)
- As of 2025: monotherapy for TRD, meaning it no longer requires a concurrent oral antidepressant
Off-label use for PTSD is supported by growing clinical trial data and is increasingly common in interventional psychiatry.
The Neuroscience: Why This Is Different
Most psychiatric medications work by adjusting monoamine levels, dopamine, serotonin, and norepinephrine. Esketamine works upstream, at the level of glutamate, the brain’s primary excitatory neurotransmitter.
Here is what happens at the neurological level:
- Esketamine blocks NMDA receptors, triggering a rapid surge of glutamate.
- That glutamate surge activates AMPA receptors, which stimulate the mTOR signaling pathway.
- mTOR activation triggers a release of BDNF (Brain-Derived Neurotrophic Factor), the brain’s key growth protein
- BDNF promotes synaptogenesis, the literal formation of new synaptic connections
The result is a period of enhanced neuroplasticity, typically lasting 24 to 72 hours post-dose, during which the brain is measurably more capable of forming new neural pathways. For patients with trauma or chronic depression, where entrenched neural circuits have become pathological, this window is clinically significant.
Think of it this way: traditional therapy is like trying to carve a new trail through compacted soil. Esketamine temporarily loosens the ground.
What the Research Shows
The original PTSD study is by Feder et al. (JAMA Psychiatry, 2014), where, for the first time, a randomized clinical trial showed that a single ketamine infusion led to a statistically significant, rapid reduction in PTSD severity compared to an active placebo in 24 hours and beyond up to seven days.
Another randomized clinical trial conducted by the same team (American Journal of Psychiatry, 2021) reported that repeated infusions resulted in even more persistent reduction in PTSD symptoms. Abdallah et al. (Neuropsychopharmacology, 2022) conducted the largest RCT on ketamine and PTSD to date, involving 158 veterans and active-duty military personnel with antidepressant-refractory PTSD.
Recent real-world evidence (2025) revealed that 77% of patients had a clinically significant response in the first six ketamine treatments for PTSD, with maximum effects seen earlier on.
Spravato (esketamine) shares the same core NMDA-antagonist mechanism with the added advantages of FDA approval, standardized dosing, REMS-certified clinical oversight, and insurance coverage for qualifying diagnoses. The neurobiological case for its use in PTSD is directly supported by the ketamine literature, and off-label use is growing under physician judgment as the research continues to develop.
The Clinical Opportunity for Therapists
This is where the conversation becomes directly relevant to your practice. Esketamine does not replace therapy. In fact, the neuroplasticity window it creates may be most valuable when paired with skilled therapeutic work.
Emerging clinical practice and early research suggest that the post-dose window, from roughly 2 hours to 72 hours after treatment, is a period of heightened psychological receptivity.
Patients usually describe:
- Decreased emotional defensiveness and more flexible thinking styles
- Enhanced capacity for working with and integrating traumatic memories without becoming flooded
- Unbinding of fixed stories and self-limiting beliefs
- Increased receptivity to relationships and attachment repair
As a clinician treating cases of PTSD, complex trauma, treatment-resistant depression, or patients who have become stuck in psychotherapy, having appointments during this time period, especially within 24 to 48 hours after the drug dose, will enhance your therapeutic effects.
This is not theoretical. It is the same integration model used in the SAINT protocol at Stanford (Cole et al., American Journal of Psychiatry, 2022) and the foundational framework for ketamine-assisted psychotherapy research currently underway at multiple academic centers.
Who Might Benefit: Patient Profiles to Consider
Not every patient is appropriate, and we conduct thorough medical and psychiatric screening before any treatment. That said, the following profiles tend to be strong candidates:
- Patients with a documented history of two or more failed antidepressant trials.
- PTSD with significant functional impairment who have not achieved remission with EMDR, CPT, or prolonged exposure alone
- Patients with chronic depression who are insightful in session but emotionally frozen between breakthroughs
- Individuals with a high degree of self-awareness but persistent emotional walls that do not respond to cognitive approaches
- Patients with active or recent suicidal ideation who need rapid stabilization
Spravato is not appropriate for patients with uncontrolled hypertension, active psychosis, certain cardiovascular conditions, or current substance use disorders involving dissociatives. We handle all screening and work collaboratively when appropriate.
How Treatment Works at Our Clinic
Spravato is administered in our REMS-certified clinic under the supervision of our supervising psychiatrist, Dr. Lisa Parsons, MD.
Every session includes:
- Pre-dose vital signs and clinical assessment
- Supervised administration of the nasal spray (56mg or 84mg, per protocol)
- A minimum two-hour monitored observation period on-site
- Post-session discharge assessment before the patient leaves
The standard induction phase is two sessions per week for four weeks, followed by a maintenance phase of once weekly or once every two weeks based on response. Patients are not permitted to drive on treatment days.
We actively encourage referral coordination and are happy to communicate treatment timing with your practice so you can plan integration sessions during the optimal window.
Partnering With Us
We built Unchained Psychiatry & Wellness to serve exactly the patients who fall through the cracks of conventional care. We are in-network with most major insurers for psychiatric services, and Spravato is covered under medical benefits for qualifying diagnoses.
If you have a patient you believe might benefit, we welcome a direct conversation. Our team is happy to do a clinical consult, answer questions about appropriateness, or walk through what the referral process looks like.
Related Topics: